Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC)

Sponsor
University of Alberta (Other)
Overall Status
Completed
CT.gov ID
NCT05374200
Collaborator
(none)
87
1
2
6.2
14.1

Study Details

Study Description

Brief Summary

The investigators have designed a guided, online, multicomponent, mind-body intervention for participants with primary biliary cholangitis. The ability of the online intervention to impact the primary and secondary outcome measures will be assessed as compared to control.

Condition or Disease Intervention/Treatment Phase
  • Other: Mind-body intervention with 1-1 support from study personnel
N/A

Detailed Description

Persons with primary biliary cholangitis (PBC) experience significantly higher rates of fatigue, stress, anxiety, depression, and impaired health related quality of life (HRQOL) as compared to the general population. Online wellness programming ranging from physical activity to mindfulness interventions has been shown to be effective in decreasing fatigue and improving mental wellness in a variety of chronic disease populations. To date, no large-scale studies have been conducted to discern whether programming of this nature impacts measures of wellbeing in PBC.

Building upon a 12-week, online, mind-body wellness program that our team previously co-developed with the Canadian PBC Society and launched as a feasibility and acceptability trial to a group of 30 individuals with PBC, the primary aim of this research project is to carry out a randomized controlled trial to assess the efficacy of the online intervention provided with brief study follow-up phone calls performed weekly by study personnel as compared to a control arm. The ability of the online program to impact the primary outcome measure of anxiety and depression as measured by the hospital anxiety and depression scale (HADS), and a range of secondary outcomes including perceived stress, fatigue, resilience, health related quality of life, physical functioning will be assessed as compared to control.

Study Design

Study Type:
Interventional
Actual Enrollment :
87 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Masking Description:
Sealed envelopes
Primary Purpose:
Treatment
Official Title:
A Randomized Control Trial Evaluating the Impact of a 12-week Mind-body Wellness Intervention in Patients With Primary Biliary Cholangitis (PBC)
Actual Study Start Date :
Oct 3, 2021
Actual Primary Completion Date :
Apr 9, 2022
Actual Study Completion Date :
Apr 9, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

Participants will receive the standard of care for PBC and access to the online intervention. During the intervention period, participants will also receive weekly brief (~10-minute) motivational interview style telephone check-ins.

Other: Mind-body intervention with 1-1 support from study personnel
The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician. Weekly brief (~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered.
Other Names:
  • Mind-body intervention
  • No Intervention: Wait list control group

    During the 12-week wait list period, participants will receive the standard of care for PBC in addition to weekly emails with motivational messages.

    Outcome Measures

    Primary Outcome Measures

    1. HADS Anxiety and Depression Scale [Baseline to 12 weeks]

      Depression and anxiety will be measured on the Hospital Anxiety and Depression Scale. The minimum score is 0, the maximum score is 21, and higher scores indicate a worse outcome.

    Secondary Outcome Measures

    1. PBC-40 [Baseline to 12 weeks]

      Six PBC specific quality of life domains will be measured on the PBC-40. For each question, the minimum value is 1, the maximum value is 5, and higher scores indicates a worse outcome. The overall scoring range varies among domains.

    2. Perceived Stress Scale [12 Weeks]

      The degree to which situations in one's life are appraised as stressful will be assessed using the Perceived Stress Scale. The minimum score is 0, the maximum score is 40, and higher scores indicate a worse outcome.

    3. Modified Fatigue Impact Scale [12 Weeks]

      The effect of fatigue on cognitive, physical, and psychosocial functioning will be measured with the modified fatigue impact scale. The minimum score is 0, the maximum score is 36, and higher scores indicate a worse outcome.

    4. Connor Davidson Resilience Scale 10 [12 Weeks]

      Resilience will be measured on the Connor Davidson Resilience Scale 10. The minimum score is 0, the maximum score is 40, and higher scores indicate a better outcome.

    5. Lower Extremity Function Scale [12 Weeks]

      Ability to perform every day tasks will be measured on the Lower Extremity Function Scale. The minimum score is 0, the maximum score is 80, and lower scores indicate worse outcomes.

    6. Capability, Opportunity, Motivation, Behavior (COM-B) Survey [12 Weeks]

      Capability, opportunity, and motivation for behavior change will be measured on the COM-B survey. The minimum score is 0, the maximum score is 60, and higher scores indicate better outcomes.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adults (≥ 18 years)

    • Identified diagnosis of PBC

    • Ability to communicate (read, write, speak) in English

    • Access to an internet connected device at home.

    Exclusion Criteria:
    • Inability to provide informed consent

    • Unsafe to participate in a low-intensity online activity program (e.g. uncontrolled angina or arrhythmia, myocardial infarction or stroke within the last 3 month, other major medical comorbidity of concern)

    • Severe psychiatric disorders (HADS score >10)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alberta Edmonton Alberta Canada T6G2C8

    Sponsors and Collaborators

    • University of Alberta

    Investigators

    • Principal Investigator: Puneeta Tandon, University of Alberta

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Alberta
    ClinicalTrials.gov Identifier:
    NCT05374200
    Other Study ID Numbers:
    • Pro00112622
    First Posted:
    May 16, 2022
    Last Update Posted:
    Aug 3, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Alberta
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 3, 2022